Compare Deckers Outdoor Corp (DECK) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs Merck & Co., Inc. — how do they compare? Deckers Outdoor Corp trades at $106.98 (market cap $14.80B), while Merck & Co., Inc. trades at $124.65 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 20.2× Deckers Outdoor Corp's market cap, and Merck & Co., Inc. pays a 2.82% dividend while Deckers Outdoor Corp pays none. Which is the better fit depends on your goals.
| DECK | MRK | |
|---|---|---|
Market Cap | $14.80B | $298.31B |
Sector | Consumer Cyclical | Health |
52-Week High | $123.91 | $129.52 |
52-Week Low | $79.54 | $77.60 |
Enterprise Value | $13.27B | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DECK trades at $107.80, up 1.71% for the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.96 exceeding the $0.83 estimate. Revenue grew to $4.99B in 2025, and net income reached $966M. Analyst consensus price target is $122.44, suggesting potential upside. Recent news highlights robust brand momentum for UGG and HOKA, with international sales growth offsetting domestic stagnation.
Outlook remains positive driven by earnings growth and strong cash flow, but risks include reliance on key brands and competitive pressures. The stock offers a reasonable valuation with a P/E of 15.36 and high profitability metrics, though technical indicators show some overbought conditions near-term.
Merck (MRK) trades at $124.03, up 0.4% today, with a bullish technical signal and strong institutional interest. Recent earnings beats and a 67.57% analyst buy rating support momentum. The company's acquisition of Terns Pharmaceuticals, announced on April 7, 2026, aims to bolster its oncology pipeline, while a dividend of $0.85 per share is scheduled for July 2026.
Outlook remains positive with a consensus price target of $137.30, though risks include rising debt levels and competitive pressures. Revenue growth is steady, but net income is projected to decline in 2026, highlighting execution challenges amid strategic expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
